Sana Biotechnology (NASDAQ:SANA - Get Free Report) released its earnings results on Monday. The company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.02, Zacks reports.
Sana Biotechnology Price Performance
NASDAQ SANA traded up $0.05 during trading on Friday, hitting $2.31. The company's stock had a trading volume of 1,007,484 shares, compared to its average volume of 3,028,740. The company has a market cap of $518.68 million, a PE ratio of -1.67 and a beta of 1.63. The business's 50 day simple moving average is $2.98 and its 200-day simple moving average is $3.19. Sana Biotechnology has a fifty-two week low of $1.52 and a fifty-two week high of $10.50.
Insiders Place Their Bets
In related news, insider Fmr Llc sold 290,912 shares of Sana Biotechnology stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $6.49, for a total transaction of $1,888,018.88. Following the completion of the sale, the insider now owns 4,541,511 shares of the company's stock, valued at $29,474,406.39. The trade was a 6.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 31.10% of the company's stock.
Analyst Ratings Changes
A number of analysts have weighed in on the company. Citizens Jmp upgraded Sana Biotechnology from a "market perform" rating to an "outperform" rating and set a $5.00 target price on the stock in a research note on Tuesday. TD Cowen upgraded Sana Biotechnology from a "hold" rating to a "buy" rating in a research note on Wednesday, January 8th. HC Wainwright restated a "buy" rating and set a $11.00 price target on shares of Sana Biotechnology in a research note on Tuesday. Finally, Jefferies Financial Group initiated coverage on Sana Biotechnology in a research note on Friday, March 14th. They set a "buy" rating and a $7.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $10.80.
View Our Latest Stock Report on Sana Biotechnology
About Sana Biotechnology
(
Get Free Report)
Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.
Featured Stories
Before you consider Sana Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sana Biotechnology wasn't on the list.
While Sana Biotechnology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
